英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:

assizes    
n. 巡回审判

巡回审判

assizes
n 1: the county courts of England (replaced in 1971 by Crown
courts) [synonym: {assizes}, {court of assize}, {court of
assize and nisi prius}]


请选择你想看的字典辞典:
单词字典翻译
Assizes查看 Assizes 在百度字典中的解释百度英翻中〔查看〕
Assizes查看 Assizes 在Google字典中的解释Google英翻中〔查看〕
Assizes查看 Assizes 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
    First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer
  • BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights
    Chemotherapy plus bevacizumab is the current standard therapy in first-line treatment of BRAF-mutated metastatic CRC (mCRC), with triplet (FOLFOXIRI) plus bevacizumab as a valid option in patients with a good performance status BRAF inhibitors are not so effective as compared to melanoma, because of various resistance mechanisms
  • U. S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen . . .
    NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc (NYSE: PFE) today announced that the U S Food and Drug Administration (FDA) has granted full approval to BRAFTOVI ® (encorafenib) in combination with cetuximab (marketed as ERBITUX ®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the
  • BRAFV600E mutant metastatic colorectal cancer: Current advances in . . .
    Finally, novel treatment strategies are available This review will discuss on currently approved treatments for BRAF V600E mutated mCRC and will try and portray the changing landscape in this setting in the era of targeted molecular therapy
  • Gastric and Rectal Administration of Encorafenib with Targeted . . .
    Abstract The activating BRAF mutation V600E occurs in 8–12% of metastatic colorectal cancers (mCRC) and is associated with peritoneal carcinomatosis (PC) and poor prognosis Targeted inhibition with the oral BRAF inhibitor encorafenib, combined with intravenous cetuximab targeting epithelial growth factor receptor (EGFR) and standard chemotherapy FOLFOX, has improved outcomes and received
  • Updates in BRAF V600E-Mutated Metastatic Colorectal Cancer
    The experts described the most important recent advances in the treatment of BRAF V600E -mutated mCRC, including data presented at the European Society for Medical Oncology (ESMO) Congress in October 2023, and the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium in January 2024
  • Treatment of Metastatic Colorectal Cancer: ASCO Guideline
    Treatment has included conventional fluorouracil (FU)–based chemotherapy, and more recently, targeted therapies have been developed for specific molecular subtypes and primary tumor sidedness 6 This guideline provides a review of the evidence for areas of uncertainty in the treatment of mCRC, including indications for targeted therapy, and
  • Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF . . .
    We, therefore, conducted a nationwide prospective observational study to evaluate the real-world effectiveness of triplet versus doublet therapy (encorafenib plus cetuximab) Patients and Methods The BEETS trial (UMIN000045530) enrolled BRAF-mutated mCRC patients who received triplet or doublet as second- or third-line treatment
  • Encorafenib, cetuximab and chemotherapy in BRAF-mutant . . . - Nature
    Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study Historically, first-line treatment of BRAF
  • Ipilimumab N01 and Sintilimab and Cetuximab in Colorectal Cancer and . . .
    Colorectal cancer (CRC) is the second leading cause of cancer-related death globally BRAF V600E mutations occur in approximately 12% of metastatic CRC (mCRC) patients, conferring an extremely poor prognosis with a median overall survival (OS) of only 11 months for standard chemotherapy





中文字典-英文字典  2005-2009